American Capital Management Inc. lifted its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 126.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 458,017 shares of the medical instruments supplier’s stock after acquiring an additional 256,127 shares during the period. American Capital Management Inc.’s holdings in OraSure Technologies were worth $7,076,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of OSUR. Fred Alger Management Inc. raised its holdings in shares of OraSure Technologies by 62.8% during the 2nd quarter. Fred Alger Management Inc. now owns 2,695,239 shares of the medical instruments supplier’s stock worth $44,391,000 after buying an additional 1,040,166 shares in the last quarter. BlackRock Inc. raised its holdings in shares of OraSure Technologies by 10.6% during the 2nd quarter. BlackRock Inc. now owns 8,480,830 shares of the medical instruments supplier’s stock worth $139,679,000 after buying an additional 810,442 shares in the last quarter. Casdin Capital LLC raised its holdings in shares of OraSure Technologies by 166.7% during the 2nd quarter. Casdin Capital LLC now owns 640,000 shares of the medical instruments supplier’s stock worth $10,541,000 after buying an additional 400,000 shares in the last quarter. Emerald Advisers Inc. PA raised its holdings in shares of OraSure Technologies by 49.1% during the 2nd quarter. Emerald Advisers Inc. PA now owns 1,007,294 shares of the medical instruments supplier’s stock worth $16,590,000 after buying an additional 331,922 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust raised its holdings in shares of OraSure Technologies by 52.7% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 836,396 shares of the medical instruments supplier’s stock worth $13,775,000 after buying an additional 288,653 shares in the last quarter. 92.00% of the stock is owned by institutional investors.
A number of research firms have recently commented on OSUR. ValuEngine raised OraSure Technologies from a “hold” rating to a “buy” rating in a report on Tuesday. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. BidaskClub raised OraSure Technologies from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 24th. Raymond James reissued a “mkt perform” rating on shares of OraSure Technologies in a report on Tuesday, October 23rd. Finally, Stephens cut OraSure Technologies from an “overweight” rating to an “equal weight” rating in a report on Monday, July 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $20.50.
In related news, Director Charles W. Patrick sold 8,000 shares of the business’s stock in a transaction on Monday, August 27th. The stock was sold at an average price of $16.29, for a total transaction of $130,320.00. Following the sale, the director now owns 54,298 shares in the company, valued at approximately $884,514.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.90% of the company’s stock.
OraSure Technologies stock opened at $14.65 on Tuesday. OraSure Technologies, Inc. has a 52 week low of $13.21 and a 52 week high of $22.22. The firm has a market cap of $868.66 million, a PE ratio of 28.73, a price-to-earnings-growth ratio of 3.34 and a beta of 1.52.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, August 8th. The medical instruments supplier reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.03. The business had revenue of $43.60 million for the quarter, compared to analyst estimates of $42.24 million. OraSure Technologies had a return on equity of 5.85% and a net margin of 8.38%. OraSure Technologies’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.09 EPS. Research analysts expect that OraSure Technologies, Inc. will post 0.34 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “American Capital Management Inc. Has $7.08 Million Holdings in OraSure Technologies, Inc. (OSUR)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/11/06/american-capital-management-inc-has-7-08-million-holdings-in-orasure-technologies-inc-osur.html.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Recommended Story: What are the reasons investors use put options?
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.